Alvotech Moves Ahead On Higher-Concentration Humira Rival
Alvotech is moving ahead with developing its higher-concentration adalimumab biosimilar after completing enrollment in a European Phase III trial.
You may also be interested in...
Alvotech has brought in a Pfizer biosimilars specialist as chief scientific officer, while Lupin has recruited a women’s health expert to head its US Specialty business. And Ian Read is to retire as Pfizer’s chairman at the start of next year.
Alvotech and Prestige Biopharma have announced a new contract manufacturing partnership for one of Prestige’s biosimilar candidates.
Cipla has firmed up a commercialization deal with Alvotech for the Icelandic developer’s high-concentration version of AbbVie’s Humira, continuing to use the licensing approach to expand its biosimilar franchise in emerging markets.